Characterization of Patients with Chronic Obstructive Pulmonary Disease Initiating Single-Inhaler Long-Acting Muscarinic Antagonist/Long-Acting β2-Agonist Dual Therapy in a Primary Care Setting in England

Autor: Requena G, Banks V, Czira A, Wood R, Tritton T, Wild R, Compton C, Duarte M, Ismaila AS

Publikováno v: International Journal of COPD, Vol Volume 17, Pp 1781-1795 (2022)

Gema Requena,1 Victoria Banks,2 Alexandrosz Czira,1 Robert Wood,2 Theo Tritton,2 Rosie Wild,2 Chris Compton,1 Maria Duarte,1 Afisi S Ismaila3,4 1Value Evidence and Outcomes, Epidemiology, GSK, R&D Global Medical, Brentford, Middlesex, UK; 2Real-world

Externí odkaz: https://doaj.org/article/15277e633377435dab660ea8e3830885

Treatment Patterns, Healthcare Utilization and Clinical Outcomes of Patients with Chronic Obstructive Pulmonary Disease Initiating Single-Inhaler Long-Acting β 2 -Agonist/Long-Acting Muscarinic Antagonist Dual Therapy in Primary Care in England.

Autor: Requena G; Value Evidence and Outcomes, GSK, R&D Global Medical, Brentford, Middlesex, UK., Banks V; Real-World Evidence, Adelphi Real World, Bollington, Cheshire, UK., Czira A; Value Evidence and Outcomes, GSK, R&D Global Medical, Brentford, Middlesex, UK., Wood R; Real-World Evidence, Adelphi Real World, Bollington, Cheshire, UK., Tritton T; Real-World Evidence, Adelphi Real World, Bollington, Cheshire, UK., Wild R; Real-World Evidence, Adelphi Real World, Bollington, Cheshire, UK., Compton C; Value Evidence and Outcomes, GSK, R&D Global Medical, Brentford, Middlesex, UK., Ismaila AS; Value Evidence and Outcomes, GSK, Collegeville, PA, USA.; Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, ON, Canada.

Publikováno v: International journal of chronic obstructive pulmonary disease [Int J Chron Obstruct Pulmon Dis] 2023 Mar 05; Vol. 18, pp. 231-245. Date of Electronic Publication: 2023 Mar 05 (Print Publication: 2023).